Calliditas: Secures a US Fast Track Designation (FTD) for Setanaxib in PBC - Redeye

Calliditas is in a good position as it is about to launch Nefecon in Europe together with Stada in early 2022. The company filed Nefecon for the US in March (priority review). It is now announcing that it has secured a FTD for the promising but more exploratory candidate Setanaxib ahead of the pivotal study expected to start later in H2 2021. With robust near term triggers, we expect value support ahead. Our value proposition for Calliditas is a base case value of SEK 280 (Bull 450, Bear 125).

Länk till analysen i sin helhet: https://www.redeye.se/research/818210/calliditas-secures-a-us-fast-track-designation-ftd-for-setanaxib-in-pbc-ahead-of-the-pivotal-study?utm_source=finwire&utm_medium=RSS